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Background. The kynurenine pathway of tryptophan oxidation is associated with central nervous system (CNS) inflammatory 
pathways. Inhibition of this pathway ameliorates CNS inflammation in rodent models of the late (meningoencephalitic) stage of 
human African trypanosomiasis (HAT). In this study, we evaluate whether the kynurenine pathway is activated in clinical HAT and 
associated with CNS inflammatory responses.
Methods. We measured cerebrospinal fluid (CSF) tryptophan and kynurenine metabolite concentrations in patients infected 
with Trypanosoma brucei rhodesiense, using liquid chromatography–mass spectrometry.
Results. Kynurenine concentration in CSF was increased in both the early and late stages of disease, with a progressive increase 
in tryptophan oxidation associated with stage progression. Kynurenine pathway activation was associated with increases in neuroin-
flammatory markers, but there was no clear relationship to neurological symptoms.
Conclusions. CNS kynurenine pathway activation occurs during HAT, including cases prior to the current diagnostic cutoff for 
late-stage infection, providing evidence for early CNS involvement in HAT. Metabolite data demonstrate that the kynurenine-3-mono-
oxygenase and kynurenine aminotransferase branches of the kynurenine pathway are active. The association between tryptophan 
oxidation and CNS inflammatory responses as measured by CSF interleukin 6 (IL-6) concentration supports a role of kynurenine 
metabolites in the inflammatory pathogenesis of late-stage HAT.
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African trypanosomiasis (sleeping sickness) is caused by the 
tsetse fly–transmitted protozoan parasites Trypanosoma brucei 
rhodesiense and Trypanosoma brucei gambiense. Infection pro-
gresses through an initial hemolymphatic stage and culminates 
in the meningoencephalitic stage, during which the invasion 
of the central nervous system (CNS) by trypanosomes leads to 
neurological disturbances, neuroinflammatory pathology, and, 
if untreated, death [1]. Treatment of the late stage of the disease is 
hampered by a posttreatment reactive encephalopathy (PTRE) 
that is associated with an exacerbation of the neuroinflamma-
tory response [2]. This is particularly severe following the use 
of melarsoprol, a trivalent arsenical drug, which is presently the 
only treatment for meningoencephalitic T. b. rhodesiense infec-
tion. The neuroinflammatory reaction plays a central role in the 
pathogenesis of the disease and the adverse reactions to treat-
ment. An improved understanding of the mechanisms direct-
ing these processes may lead to modifications of the treatment 
strategy that would limit the extent of the PTRE. Indeed, both 
nonsteroidal antiinflammatory drugs and counterinflammatory 
cytokine treatments have been demonstrated to reduce neuro-
pathology in animal models of meningoencephalitic human 
African trypanosomiasis (HAT) infections [3, 4].
The kynurenine pathway is the main pathway of trypto-
phan degradation. An outline of the key enzymes and pathway 
metabolites is provided in Supplementary Figure S1 for refer-
ence. Kynurenine pathway metabolites have a range of activi-
ties in the CNS, including neuroprotective, neurotoxic, and 
immunosuppressive functions, and the pathway is activated in 
association with inflammatory pathways in the CNS in both 
infectious diseases [5–7] and neurodegenerative conditions 
[8–10]. Depletion of the first compound on the pathway (tryp-
tophan), together with the actions of kynurenine metabolites 
on immune cell function [11–13], may lead to limitations on 
the proliferation of both microbial pathogens and immune 
cells in the relevant tissues. Evidence for a role of kynurenine 
pathway metabolites in the pathogenesis of meningoenceph-
alitic HAT was recently obtained in a mouse model [14]. 
Administration of 3,4-dimethoxy-N-[4-(3-nitrophenyl)thi-
azol-2-yl]benzenesulfonamide (Ro-61–8048; [15]), an inhibitor 
of kynurenine-3-monooxygenase (KMO), in that model led to a 
reduction in neuroinflammatory response, suggesting that such 
inhibitors may offer potential therapeutic tools to ameliorate 
PTRE in clinical cases. Since this pathway is enmeshed in the 
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CNS inflammatory response, it is also possible that kynurenine 
metabolites might also act as biomarkers for meningoenceph-
alitic disease, for which there is an urgent need to develop 
more-precise stage diagnostic criteria [16].
In this study, we use clinical samples of CSF from patients 
with HAT to establish whether kynurenine pathway activation 
occurs in the human condition. We assess whether kynurenine 
pathway metabolites are associated with either neuroinflamma-
tory markers or neurological sequelae and evaluate their poten-
tial as stage diagnostic markers.
PATIENTS AND METHODS
This was a retrospective study involving cerebrospinal fluid 
samples from 40 patients with HAT and 10 uninfected individ-
uals. The samples in this study were collected under protocols 
approved by ethics committees in Uganda (Uganda National 
Council for Science and Technology) and the United Kingdom 
(North of Scotland Research Ethics Committee), conforming 
to the principles of the Declaration of Helsinki. Ethical consent 
forms were designed in English and translated into local lan-
guages. Consent was given as a signature or a thumbprint after 
verbal explanation. For those aged <18 years, consent was given 
by the legal guardian.
A total of 40 patients with HAT were recruited at Lwala 
Hospital, Kaberamaido District and Serere Health Center 
(Serere District, Eastern Region) between November 2008 and 
March 2010. Full details of the recruitment protocols, treat-
ment regimens, disease progression characteristics, and clini-
cal examination methods have been published elsewhere [17]. 
Patients with intercurrent malaria, filariasis, or schistosomiasis 
were excluded. Cerebrospinal fluid (CSF) samples were col-
lected from all patients as part of normal diagnostic and staging 
procedures. Staging was performed in accordance with World 
Health Organization criteria [18], in which late-stage infection 
was defined by the presence of parasites in the lumbar CSF and/
or a CSF white blood cell count (WBC) of >5 cells/µL. A further 
10 control CSF samples were obtained from patients with sus-
pected HAT who were subsequently confirmed as uninfected. 
Aliquots of 1–2 mL of CSF were centrifuged (at 450 × g for 10 
minutes at 4°C), and the supernatant was frozen and then main-
tained in liquid nitrogen until transfer to the United Kingdom. 
After transport via airfreight (involving storage for 24 hours on 
dry ice), samples were maintained at −80°C until analysis.
Kynurenine Pathway Metabolite Analysis
Liquid Chromatography–Tandem Mass Spectrometry
Tryptophan, kynurenine, and kynurenine metabolites were 
measured by liquid chromatography–tandem mass spectrom-
etry, using a CTC PAL HTS-XT, Agilent 1260 Infinity liquid 
chromatograph and an AB SCIEX 6500 QTRAP mass spec-
trometer (AB Sciex UK, Warrington, United Kingdom). All 
results were calculated in Analyst 1.6.
Analytical Chemicals and Reagents
Tryptophan, kynurenine, kynurenic acid, anthranilic acid, 
3-hydroxykynurenine, 3-hydroxyanthranilic acid, xanthurenic 
acid, picolinic acid, and quinolinic acid were obtained from Sigma 
Aldrich (Poole, United Kingdom). The stable isotope–labeled 
internal standards were 2H5-tryptophan (QMx Laboratories, 
Thaxted, United Kingdom), 2H6-kynurenine sulfate and 2H5-
kynurenic acid (CK isotopes, Ibstock, United Kingdom), and 
2H3-picolinic acid and 13C3,15N-quinolinic acid (LGC standards, 
Teddington, United Kingdom). Acetonitrile and methanol 
were obtained from Rathburn Chemicals (Walkerburn, United 
Kingdom) and Fisher Scientific UK (Loughborough, United 
Kingdom), respectively.
Standards of each analyte were used to automatically tune in 
multiple reaction monitoring (MRM) mode. Transition opti-
mizations were performed manually. Xanthurenic acid was 
significantly more sensitive in negative ion mode, but, with the 
chromatographic conditions used, there was massive matrix ion 
suppression. Consequently, xanthurenic acid was measured in 
positive ion mode.
Because analyte retention times on Chirobiotic-T columns 
tend to be matrix dependent, there is a critical requirement for 
the appropriate stable isotope internal standards. Consequently, 
when stable isotopes were unavailable, 2 separate transitions, 
when possible, were used to calculate and then confirm the result.
CSF Sample Preparation
For measurement of all analytes, 60  µL of blank (deionized 
water), aqueous standards, and CSF were mixed with 10 mL of 
the stable isotope mix (20 µL of 10 mM 2H5-tryptophan; 2 µL 
of 16 mM 2H6-kynurenine sulfate; 2 µL of 2 mM 2H5-kynurenic 
acid; 5 µL of 15 mM 13C3,15N-quinolinic acid; and 5 µL of 40 mM 
2H3-picolinic acid) in 75 µL of methanol, mixed by vortexing, 
and centrifuged for 5 minutes at 20 817 × g. Supernatants were 
transferred to a 96-well deep well polypropylene plate, a sealing 
mat was applied, and the plate was placed in the CTC autosam-
pler and cooled to 7.5°C, awaiting injection.
Positive Ion MRM Mode Acquisitions
Isocratic chromatography of tryptophan and kynurenine, 
kynurenic acid, anthranilic acid, 3-hydroxykynurenine, 
3-hydroxyanthranilic acid, and xanthurenic acid (injection vol-
ume, 10 µL; data acquisition time, 7 minutes) was performed on 
a 5-µm Astec Chirobiotic-T column (10 cm [length] × 2.1 mm 
[internal diameter] guard column), using a 1:1 ratio of acetoni-
trile to water with 0.025% formic acid at a flow rate of 200 µL/
minute. Tandem mass spectrometry parameters were as follows: 
curtain gas, 40; CAD gas, medium; ion source voltage, 5250 V; 
gas temperature, 400°C; gas 1, 25; and gas 2, 25.
Negative Ion MRM Mode Acquisitions
Isocratic chromatography of quinolinic acid and picolinic acid 
(injection volume, 10 µL; data acquisition time, 4 minutes) was 
808 • JID 2017:215 (1 March) • Sternberg et al
performed on a 5-µm Astec Chirobiotic-T (10  cm [length] × 
2.1 mm [internal diameter] guard column), using 62.5% water/
acetonitrile at a flow rate of 225 µL/minute. Tandem mass spec-
trometry parameters were as follows: curtain gas, 45; CAD gas, 
medium; ion source voltage, −4500 V; gas temperature, 400°C; 
gas 1, 30; and gas 2, 30. Full details of mass spectrometry condi-
tions are described by Forrest et al [19].
CSF Cytokine Assays
Interferon γ (IFN-γ), interleukin 6 (IL-6), and interleukin 10 
(IL-10) concentrations were measured using a solid-phase 
sandwich enzyme-linked immunosorbent assay (OptiEIA; BD 
Pharmingen), as described previously [20]. Biological limits of 
detection were 1.8, 8.3, and 1.6 pg/mL, respectively
Statistical Analysis
CSF analyte data were left skewed and could not be consis-
tently transformed. Therefore, nonparametric inferential sta-
tistical analyses (indicated in figure legends or the text) were 
performed using JMP10.0 (SAS, Cary, NC). For descriptive and 
inferential statistical analysis, results below the limit of detec-
tion were adjusted to 0.5 times the limit of detection. For analy-
sis of diagnostic power, areas under the receiver operator curve 
(AUROCs) were calculated using the logistic modeling platform 
in JMP 10.0. Significance values in multiple correlation analyses 
were adjusted as described by Benjamini and Hochberg [21].
RESULTS
Patients With HAT and Controls
A summary of the parasitological and demographic character-
istics and neurological assessment of the patients is presented 
in Table  1. Neurological symptoms (gait ataxia, somnolence, 
tremor, and abnormal Glasgow Coma Scale score) were pre-
dominantly observed in late-stage cases. Neurological assess-
ments were not available for control subjects.
Kynurenine Pathway Metabolite Concentrations in HAT Cases
In late-stage HAT cases, CSF tryptophan levels were significantly 
lower than those in either early stage cases or uninfected sam-
ples (Table 2), although the range of outlying concentrations in 
both early stage and late-stage cases demonstrates that the CSF 
tryptophan concentration is of limited stage diagnostic value 
(AUROC = 0.72). Conversely, the L-kynurenine concentration 
was significantly increased in all HAT cases (both early and late 
stage), compared with findings for uninfected individuals.
The ratio of CSF kynurenine to tryptophan was calculated as 
an index of tryptophan oxidation via indoleamine-2,3-dioxy-
genase (IDO) and tryptophan-2,3-dioxygenase (TDO) activi-
ties and indicated significantly increased tryptophan oxidation 
in late-stage HAT cases (Figure 1A), although, as in the case of 
tryptophan, the stage diagnostic power of this parameter was 
weak (AUROC = 0.68).
Metabolites representing subsequent stages of the kynurenine 
pathway were also analyzed (an outline of the key enzymes and 
pathways is provided in Supplementary Figure  1). Although 
increases in 3-hydroxykynurenine concentration in patients 
with HAT (both early and late stage) suggested activation of the 
KMO branch of the pathway, this was not significant, proba-
bly because of the small size of the control group. We there-
fore examined the correlation coefficients of L-kynurenine 
metabolites within the infection cases as a means to identify 
the dominant kynurenine metabolic pathways in patients with 
HAT (Table 3). Significant correlations of kynurenine concen-
tration with those of 3-hydroxykynurenine and kynurenic acid 
provides evidence of KMO and kynurenine aminotransferase 
(KAT) activity.
Modulation of KMO and KAT with infection stage was 
assessed by analysis of the product to substrate ratios. Kynurenic 
acid to kynurenine ratios were significantly reduced, com-
pared with control values, in early stage and late-stage HAT 
cases (Figure 1B), indicating inhibition of the KAT branch of 
the kynurenine pathway. On the other hand, there was no sig-
nificant change in 3-hydroxykynurenine to kynurenine ratios 
between infected and control subjects (Figure 1C), suggesting 
that the KMO branch of the pathway was predominant.
We were unable to measure the terminal metabolites—xan-
thurenic acid, quinolinic acid, and picolinic acid—that have 
previously been detected by this tandem mass spectrometry 
method in brain samples [19]. CSF levels of xanthurenic acid 
Table 1. Demographic and Symptomatic Characteristics of Uninfected Controls and Patients With Early Stage or Late Stage Human African Trypanosomiasis
Characteristic Controls (n = 10) Early Stage (n = 11) Late Stage (n = 29)
Age, y, median (range) 30 (21–69) 22 (15–70) 22 (14–45)
Male sex; female sex 6; 4 3; 8 14; 15
CSF WBC count, cells/µL, median (range) NA 3 (1–5) 25 (8–308)
Somnolence NA 0/11 16/29a
Gait ataxia NA 1/11 11/27a,b
Tremors NA 1/11 11/29a
GCS score <15 NA 0/11 7/29
Abbreviations: CSF, cerebrospinal fluid; GCS, Glasgow Coma Scale; NA, not applicable; WBC, white blood cell.
aSignificantly greater, compared with patients with early stage HAT (P < .05 by the χ2 test).
bData were unavailable for 2 patients with late-stage HAT.
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were <0.5  nmol/L, and accurate quantification would require 
the concentration of larger sample volumes prior to analysis.. 
The measurement of CSF levels of quinolinic acid and picolinic 
acid proved problematic owing to the small sample volumes 
available and very high ion suppression.
The ratio of 3-hydroxy-anthranilic acid to anthranilic acid 
was significantly reduced in late-stage HAT cases as compared 
to controls (Figure  1D), consistent with inflammatory activa-
tion [22], although because of the large variance in early stage 
cases this parameter is of no stage diagnostic value.
Figure 1.  A, Ratios of cerebrospinal fluid concentrations, in nmol/L, of kynurenine (Kyn) to tryptophan (Trp; A), kynurenic acid (KA) to Kyn (B), 3-hydroxykynurenine (3-HK) to 
Kyn (C), and 3-hydroxyanthranilic acid (3-HAA) to anthranilic acid (AA; D) in 10 uninfected controls, 11 patients with early stage human African trypanosomiasis (HAT), and 29 
patients with late-stage HAT. Boxes show median values and interquartile ranges. Whiskers indicate ranges from the 10th to 90th percentiles. *P < .05, by the Dunn multiple 
comparisons test, compared with uninfected controls.
Table 2. Cerebrospinal Fluid Concentrations of Tryptophan, Kynurenine, and Downstream Metabolites in Uninfected Controls and Patients With Early 
Stage or Late-Stage Human African Trypanosomiasis
Variable
Concentration, nmol/L
Uninfected (n = 10) Early Stage (n = 11) Late Stage (n = 29) P
Tryptophan 1003.5 (531.6–1195) 937 (430–1560) 335 (98.8–634) <.05a
Kynurenine 112.5 (65.75–198) 330 (190–460)§ 226 (148–729) <.05a
Kynurenic acid 4.21(1.89–10.4) 7.37 (5.2–9.29) 6.54 (2.88–11)
Anthranilic acid 1.35 (1.02–2.25) 1.81 (1.57–2.08) 1.73 (1.49–2.31)
3-HK 10.3 (8.48–12.05) 15.2 (9.14–36.6) 15.4 (7.93–27.9)
3-HAA 0.25 (0.25–0.64) 0.25 (0.25–0.48) 0.25 (0.25-0.25)
Data are median values (interquartile ranges).
Abbreviations: 3-HAA, 3-hydroxyanthranilic acid; 3-HK, 3-hydroxykynurenine.
aBy the Dunn multiple comparisons test, compared with uninfected controls.
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Kynurenine Pathway and CNS Immune Activation
Stage progression in HAT was associated with significant 
increases in CSF levels of IL-6, IL-10, and IFN-γ (Table  4). 
Because the kynurenine to tryptophan ratio was also elevated in 
late-stage cases, we investigated whether the kynurenine path-
way was associated with CNS immune activation, as measured 
by CSF cytokine concentration and white blood cell counts. 
There were strong and highly significant correlations between 
kynurenine to tryptophan ratios and CSF white blood cell 
count, IL-6 concentration, and IL-10 concentration (Table 5). 
The ratio of 3-hydroxy-anthranilic acid to anthranilic acid, 
which is inversely associated with neuroinflammatory activa-
tion in other pathologies [22], also exhibited a significant nega-
tive correlation with CSF IL-6 concentration (Table 5).
Because the KMO inhibitor Ro-61–8048 ameliorated neu-
roinflammatory responses in a mouse model of HAT [14], we 
investigated whether the primary metabolic product of this 
enzyme, 3-hydroxykynurenine, would exhibit a positive correla-
tion with markers of neuroinflammation. However, no signifi-
cant relationships were observed with the IL-6 level (Spearman 
ρ = 0.19), the IFN-γ level (ρ = −0.11), or CSF WBC pleocytosis 
(ρ = −0.04).
Kynurenine Pathway and Neurological Symptoms
All patients were subject to neurological assessment on enter-
ing the study. There was no association between the concen-
tration of any of the kynurenine metabolites and presentation 
with tremor, gait ataxias, or evidence of coma, as measured by 
a Glasgow Coma Scale score of <15. In somnolent patients, we 
did observe increased tryptophan oxidation activity (median 
kynurenine to tryptophan ratio, 1.40 in somnolent patients and 
0.52 in nonsomnolent patients; P < .05 by the Mann–Whitney 
U test). Because somnolence was strongly associated with late 
stage cases (Table  1), we examined tryptophan oxidation in 
late-stage cases only. In this analysis, the apparent difference in 
kynurenine to tryptophan ratios between somnolent cases and 
nonsomnolent cases (median, 1.39 and 0.68, respectively) was 
not significant (P = .08).
DISCUSSION
In this study, the concentrations of tryptophan and metabolites 
of the kynurenine pathway were measured in relation to dis-
ease status and CNS inflammatory responses in patients with 
HAT. There were increases in kynurenine concentration in the 
CSF during early stage and late-stage disease, with an increased 
kynurenine to tryptophan ratio in late-stage disease, in which 
depletion of tryptophan was evident. The increased kynurenine 
concentration in the CSF of patients with early stage HAT pro-
vides evidence for upregulation of CNS tryptophan metab-
olism before the onset of the late stage as defined by current 
diagnostic criteria. This finding is consistent with similar results 
in an independent clinical study of intrathecal immunoglob-
ulin synthesis in T. b. rhodesiense HAT [23]. When combined 
with recent data on early CNS involvement in rodent models of 
African trypanosomiasis [24], these findings question the bio-
logical relevance of current stage diagnostic criteria.
The correlation between kynurenine and 3-hydroxyky-
nurenine levels and between kynurenine and kynurenic acid are 
consistent with activity along both the KMO and KAT branches 
of the kynurenine pathway. The reduced product/substrate con-
centrations observed in infected individuals as compared to 
controls for the KAT branch but not for the KMO branch of the 
pathway indicate that KMO is the predominant pathway acti-
vated during infection, but for both pathways there appears to 
be no change in the relative activities of the 2 enzymes during 
progression from early stage to late-stage HAT.
While the immediate metabolic product of KMO, 
3-hydroxykynurenine, is known to have neurotoxic activity 
[25–29], it is unlikely to be involved in the neuropathology 
of HAT since there was no relationship between its concen-
tration in the CSF and either inflammatory markers (white 
blood cell counts or cytokines) or neurological symptoms. It 
remains possible that quinolinic acid, a downstream metabolite 
Table 3.  Relationships of Cerebrospinal Fluid Kynurenine Concentration and Downstream Metabolites in Patients With Human African Trypanosomiasis
Variable 3-HK P Anthranilic Acid P 3-HAA P Kynurenic Acid P
Kynurenine 0.47 <.001 0.25 NS 0.11 NS 0.56 <.001
3-HK … … 0.28 NS 0.08 NS 0.13 NS
Anthranilic acid … … … … 0.03 NS 0.33 NS
3-HAA … … … … … … 0.05 NS
Data are Spearman rank correlation coefficients. Significance was corrected using the Benjamini-Hochberg method for multiple-test false-discovery rates.
Abbreviations: NS, not significant; 3-HAA, 3-hydroxyanthranilic acid; 3-HK, 3-hydroxykynurenine.
Table  4.  Cerebrospinal Fluid Concentration of Cytokines, by Human 
African Trypanosomiasis Stage
Cytokine
Concentration, by Disease Stage, pg/mL
Early (n = 11) Late (n = 29) Pa
IL-6 4.2 (4.2–6.0) 56.1 (4.2–222.1) <.005
IL-10 9.8 (0.8–78.5) 326.4 (106.1–454.1) <.005
IFN-γ 0.9 (0.9–12.9) 22.0 (0.9–38.4) <.05
Data are median values (interquartile ranges).
Abbreviations: IFN-γ, interferon γ; IL-6, interleukin 6; IL-10, interleukin 10.
aBy the Mann–Whitney test, compared with patients with early stage disease.
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of 3-hydroxy-kyurenine, could be involved, because it also has 
marked neurotoxicity via NMDA receptors and other mecha-
nisms [30]. The ratio between 3-hydroxy-anthranilic acid and 
anthranilic acid is inversely related to the presence of inflam-
mation [22] and, interestingly, was significantly reduced in late-
stage CSF samples. In addition, this metabolite was negatively 
correlated to the inflammatory CSF marker IL-6.
CNS immune activation in HAT was apparent in increases 
in both inflammatory (IL-6 and IFN-γ) and counterinflam-
matory (IL-10) cytokines with stage progression, and this was 
also reflected in increased CSF white blood cell concentra-
tion. These increases have been described in previous studies 
of patients with HAT [31]. Our data demonstrate an associ-
ation between tryptophan oxidation and CNS inflammatory 
activity, as reflected in IL-6 concentration. While it cannot be 
stated with certainty whether this results from increased activ-
ity of IDO in the CNS and immune system cells or of TDO 
in the liver, the former is more likely because it is induced 
and activated by IFN-γ, whereas TDO is regulated primarily 
by stress-induced corticosteroids. Interestingly, the ratio of 
3-hydoxy-anthranilic acid to anthranilic acid, which has been 
shown to be negatively associated with inflammatory pathol-
ogy in other conditions [22], also demonstrated a significant 
negative relationship with the CSF IL-6 concentration but not 
IL-10 concentration in patients with HAT and may represent 
the first discrimination of the inflammatory response in the 
brain from the counterinflammatory regulation by IL-10 [32]. 
Cytokine correlations with the kynurenine to tryptophan ratio 
have been demonstrated in other disorders, such as cancer 
[33], meningitis [34], and atherosclerosis [35]. Activation of 
IDO induces the production of IL-10 [36, 37], which is a well 
characterized CNS response in HAT, while IL-10 has in turn 
been reported to inhibit the IFN-γ–induced activation of IDO 
in neurons [38]. This may reflect a novel mechanism by which 
coordination of the kynurenine pathway and inflammatory/
counterinflammaotry regulation influence neuropathogenesis 
in HAT [32].
Because the kynurenine pathway includes potent modula-
tors of neuronal function, such as quinolinic acid as an agonist 
[39] and kynurenic acid as an antagonist [40, 41], at NMDA-
sensitive glutamate receptors, the relationship may provide a 
potential explanation of some of the neurological symptoms of 
HAT. However, in this study only somnolence was associated 
with increased kynurenine pathway activation, and because this 
association was confounded with the increased activation in the 
late stage of disease, a larger scale clinical study is required to 
establish the significance of this relationship.
In previous work we demonstrated that the inhibition of 
KMO leads to an amelioration of neuropathology in a mouse 
model of HAT CNS disease [14]. Similarly, in a murine form 
of cerebral malaria, KMO inhibition prevented the death 
of the infected mice, prolonging the normal 7-day survival 
period to at least 21 days [5]. While the results presented here 
in patients with HAT indicate that the initial product of KMO, 
3-hydroxykynurenine, is not related to either inflammatory 
pathology or disease symptoms, it is possible that downstream 
kynurenine pathway metabolites such as quinolinic acid [30] 
induce HAT neuropathology, and further work using exper-
imental models is required to understand the mechanistic 
consequences of KMO inhibition and whether this offers 
a potential avenue in the search for novel treatments of this 
and other CNS conditions exhibiting neuroinflammatory 
pathologies.
In conclusion, this study indicates that the kynurenine 
pathway is integrally involved in the development of the 
neuroinflammatory response associated with clinical cases 
of African trypanosomiasis. Although it may not be possible 
to utilize these metabolites as biomarkers for disease staging, 
the study provides further evidence that the current clini-
cal stage diagnostic criteria may not reflect clinically rele-
vant pathological processes in the CNS. In a retrospective 
study such as this, causal relationships cannot be precisely 
defined, but further work in experimental models will offer 
the potential to understand the mechanistic relationships 
of the kynurenine pathway and HAT neuropathology and 
hence provide a route to novel treatment strategies that may 
minimize or eliminate the risk of a severe PTRE in these crit-
ically ill patients.
Table 5. Correlations of the Ratio of Kynurenine (Kyn) to Tryptophan (Trp) and the Ratio of 3-Hydroxyanthranilic Acid (3-HAA) to Anthranilic Acid (AA) to 
Cerebrospinal Fluid Markers of Immune Activation
Variable
3-HAA 
to AA 
Ratio P WBC Count P IL-6 Concentration P IL-10 Concentration P IFN-γ Concentration P
Kyn to Trp ratio 0.19 NS 0.38 <.03 0.47 <.03 0.56 <.01 0.26 NS
3-HAA to AA ratio … 0.12 −0.44 <.03 −0.25 NS −0.05 NS
WBC count … … 0.33 NS 0.55 <.01 0.51 <.02
IL-6 concentration … … … 0.73 <.001 0.35 NS
IL-10 concentration … … … … 0.61 <.01
Data are Spearman rank correlation coefficients. Significance was corrected using the Benjamini-Hochberg method for multiple-test false-discovery rates.
Abbreviations: IFN-γ, interferon γ; IL-6, interleukin 6; IL-10, interleukin 10; NS, not significant; WBC, white blood cell.
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